13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q4 2025 · Filed February 17, 2026 · Accession 0001193125-26-053268
Total Value
$286.5M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Nuvation Bio | NUVB | 8,081,089 | $72.4M | 25.27% |
| 2 | BridgeBio Oncology Therapeutics Inc. | BBOT | 3,289,661 | $41.2M | 14.37% |
| 3 | Beta Bionics Inc. | BBNX | 1,316,183 | $40.1M | 14.00% |
| 4 | Bicara Therapeutics Inc. | BCAX | 2,204,650 | $37.1M | 12.95% |
| 5 | Kestra Med Technologies Ltd | BEKE | 1,373,591 | $36.4M | 12.71% |
| 6 | Upstream Bio Inc. | UPB | 1,326,293 | $36.0M | 12.57% |
| 7 | enGene Holdings Inc. | ENGNW | 876,357 | $7.9M | 2.76% |
| 8 | Alumis Inc. | ALMS | 653,223 | $6.4M | 2.23% |
| 9 | Sana Biotechnology, Inc. | SANA | 843,750 | $3.4M | 1.20% |
| 10 | ImageneBio, Inc. | IMA | 455,361 | $3.1M | 1.10% |
| 11 | Replimune Group | REPL | 248,672 | $2.4M | 0.84% |